0000899243-20-000655.txt : 20200106 0000899243-20-000655.hdr.sgml : 20200106 20200106210017 ACCESSION NUMBER: 0000899243-20-000655 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200102 FILED AS OF DATE: 20200106 DATE AS OF CHANGE: 20200106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gerard Christopher CENTRAL INDEX KEY: 0001694097 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 20511895 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY, SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-02 0 0000896262 AMEDISYS INC AMED 0001694097 Gerard Christopher 3854 AMERICAN WAY, SUITE A BATON ROUGE LA 70816 0 1 0 0 Chief Operating Officer Common Stock 2020-01-02 4 S 0 240 164.68 D 24091 D Common Stock 2020-01-02 4 S 0 100 166.27 D 23991 D Common Stock 2020-01-02 4 S 0 10 167.83 D 23981 D Common Stock 279 I Through 401(k) Plan The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.17 to $165.12, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. The information in this report is based on a plan statement dated as of September 30, 2019. /s/ David L. Kemmerly, pursuant to a power of attorney 2020-01-06